{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T20:05:50Z","timestamp":1760645150836},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2006,1,17]],"date-time":"2006-01-17T00:00:00Z","timestamp":1137456000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2006,1,17]],"date-time":"2006-01-17T00:00:00Z","timestamp":1137456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacogenomics J"],"published-print":{"date-parts":[[2006,9,1]]},"DOI":"10.1038\/sj.tpj.6500366","type":"journal-article","created":{"date-parts":[[2006,1,17]],"date-time":"2006-01-17T08:30:40Z","timestamp":1137486640000},"page":"327-332","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Topiramate stimulates glucose transport through AMP-activated protein kinase-mediated pathway in L6 skeletal muscle cells"],"prefix":"10.1038","volume":"6","author":[{"given":"E","family":"Ha","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S V","family":"Yim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K H","family":"Jung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S H","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L T","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M J","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S J","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B K","family":"Choe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H H","family":"Baik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J H","family":"Chung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J W","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2006,1,17]]},"reference":[{"key":"BF6500366_CR1","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1038\/oby.2000.84","volume":"8","author":"F Picard","year":"2000","unstructured":"Picard F, Deshaies Y, Lalonde J, Samson P, Richard D . Topiramate reduces energy and fat gains in lean (Fa\/?) and obese (fa\/fa) Zucker rats. Obes Res 2000; 8: 656\u2013663.","journal-title":"Obes Res"},{"key":"BF6500366_CR2","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.4088\/JCP.v64n1109","volume":"64","author":"SP Hoopes","year":"2003","unstructured":"Hoopes SP, Reimherr FW, Hedges DW, Rosenthal NR, Kamin M, Karim R et al. Treatment of bulimia nervosa with topiramate in a randomized, double-blind, placebo-controlled trial, part 1: improvement in binge and purge measures. J Clin Psychiatry 2003; 64: 1335\u20131341.","journal-title":"J Clin Psychiatry"},{"key":"BF6500366_CR3","doi-asserted-by":"publisher","first-page":"368","DOI":"10.4088\/JCP.v61n0508","volume":"61","author":"NA Shapira","year":"2000","unstructured":"Shapira NA, Goldsmith TD, McElroy S . Treatment of binge disorder with topiramate: a clinical case series. J Clin Psychiatry 2000; 61: 368\u2013372.","journal-title":"J Clin Psychiatry"},{"key":"BF6500366_CR4","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1002\/eat.10154","volume":"33","author":"JG Barbee","year":"2003","unstructured":"Barbee JG . Topiramate in the treatment of severe bulimia nervosa with comorbid mood disorders: a case series. Int J Eat Disord 2003; 33: 468\u2013472.","journal-title":"Int J Eat Disord"},{"key":"BF6500366_CR5","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1038\/oby.2003.102","volume":"11","author":"GA Bray","year":"2003","unstructured":"Bray GA, Hollander P, Klein S, Kushner R, Levy B, Fitchet M et al. A 6-Month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity. Obes Res 2003; 11: 722\u2013733.","journal-title":"Obes Res"},{"key":"BF6500366_CR6","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1034\/j.1399-5618.2002.01182.x","volume":"4","author":"PA Schmidt do Prado-Lima","year":"2002","unstructured":"Schmidt do Prado-Lima PA, Bacaltchuck J . Topiramate in treatment-resistant depression and binge-eating disorder. Bipolar Disord 2002; 4: 271\u2013273.","journal-title":"Bipolar Disord"},{"key":"BF6500366_CR7","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/S0924-9338(01)00562-4","volume":"16","author":"KN Roy Chengappa","year":"2001","unstructured":"Roy Chengappa KN, Levine J, Rathore D, Parepally H, Atzert R . Long-term effects of topiramate on bipolar mood instability, weight change and glycemic control: a case-series. Eur Psychiatry 2001; 16: 186\u2013190.","journal-title":"Eur Psychiatry"},{"issue":"Suppl 7","key":"BF6500366_CR8","first-page":"4","volume":"65","author":"DE Casey","year":"2004","unstructured":"Casey DE, Haupt DW, Newcomer JW, Henderson DC, Sernyak MJ, Davidson M et al. Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. J Clin Psychiatry 2004; 65 (Suppl 7): 4\u201318.","journal-title":"J Clin Psychiatry"},{"issue":"5 Suppl 1","key":"BF6500366_CR9","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1097\/01.jcp.0000142282.62336.e9","volume":"24","author":"HA Nasrallah","year":"2004","unstructured":"Nasrallah HA, Newcomer JW . Atypical antipsychotics and metabolic dysregulation: evaluating the risk\/benefit equation and improving the standard of care. J Clin Psychopharmacol 2004; 24 (5 Suppl 1): S7\u2013S14.","journal-title":"J Clin Psychopharmacol"},{"key":"BF6500366_CR10","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1176\/appi.psy.42.3.279","volume":"42","author":"DW Haupt","year":"2001","unstructured":"Haupt DW, Newcomer JW . Risperidone-associated diabetic ketoacidosis. Psychosomatics 2001; 42: 279\u2013280.","journal-title":"Psychosomatics"},{"key":"BF6500366_CR11","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/sj.mp.4000566","volume":"5","author":"A Lacruz","year":"2000","unstructured":"Lacruz A, Baptista T, de Mendoza S, Mendoza-Guillen JM, Hern\u00e1ndez L . Antipsychotic drug-induced obesity in rats: correlation between leptin, insulin and body weight during sulpiride treatment. Mol Psychiatry 2000; 5: 70\u201376.","journal-title":"Mol Psychiatry"},{"key":"BF6500366_CR12","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1176\/appi.ajp.160.2.290","volume":"160","author":"JP Lindenmayer","year":"2003","unstructured":"Lindenmayer JP, Czobor P, Volavka J, Citrome L, Sheitman B, McEvoy JP et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry 2003; 160: 290\u2013296.","journal-title":"Am J Psychiatry"},{"issue":"Suppl 1","key":"BF6500366_CR13","first-page":"1","volume":"19","author":"JW Newcomer","year":"2005","unstructured":"Newcomer JW . Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005; 19 (Suppl 1): 1\u201393.","journal-title":"CNS Drugs"},{"key":"BF6500366_CR14","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1176\/appi.ajp.159.4.561","volume":"159","author":"MJ Sernyak","year":"2002","unstructured":"Sernyak MJ, Leslie DL, Alarcon RD, Losonczy MF, Rosenheck R . Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 2002; 159: 561\u2013566.","journal-title":"Am J Psychiatry"},{"key":"BF6500366_CR15","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.schres.2004.03.024","volume":"71","author":"H Jin","year":"2004","unstructured":"Jin H, Meyer JM, Jeste DV . Atypical antipsychotics and glucose dysregulation: a systematic review. Schizophr Res 2004; 71: 195\u2013212.","journal-title":"Schizophr Res"},{"key":"BF6500366_CR16","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/S0920-1211(03)00039-1","volume":"54","author":"M \u00c4ngehagen","year":"2003","unstructured":"\u00c4ngehagen M, Ben-Menachem E, R\u00f6nnb\u00e4ck L, Hansson E . Topiramate protects against glutamate- and kainite-induced neurotoxicity in primary neuronal-astroglial cultures. Epilepsy Res 2003; 54: 63\u201371.","journal-title":"Epilepsy Res"},{"key":"BF6500366_CR17","doi-asserted-by":"publisher","first-page":"41029","DOI":"10.1074\/jbc.M102824200","volume":"276","author":"X Xi","year":"2001","unstructured":"Xi X, Han J, Zhang JZ . Stimulation of glucose transport by AMP-activated protein kinase via activation of p38 mitogen-activated protein kinase. J Biol Chem 2001; 276: 41029\u201341034.","journal-title":"J Biol Chem"},{"key":"BF6500366_CR18","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1096\/fj.02-1125com","volume":"17","author":"K Lemieux","year":"2003","unstructured":"Lemieux K, Konrad D, Klip A, Marette A . The AMP-activated protein kinase activator AICAR does not induce GLUT4 translocation to transverse tubules but stimulates glucose uptake and p38 mitogen-activated protein kinases \u00e1 and \u00e2 in skeletal muscle. FASEB J 2003; 17: 1658\u20131665.","journal-title":"FASEB J"},{"key":"BF6500366_CR19","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1146\/annurev.biochem.67.1.821","volume":"67","author":"DG Hardie","year":"1998","unstructured":"Hardie DG, Carling D, Carlson M . The AMP-activated\/SNF1 protein kinase subfamily: metabolic sensors of the eukaryotic cell. Annu Rev Biochem 1998; 67: 821\u2013855.","journal-title":"Annu Rev Biochem"},{"key":"BF6500366_CR20","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/S0968-0004(98)01340-1","volume":"24","author":"BE Kemp","year":"1999","unstructured":"Kemp BE, Mitchelhill KI, Stapleton D, Michell BJ, Chen ZP, Witters LA . Dealing with energy demand: the AMP-activated protein kinase. Trends Biochem Sci 1999; 24: 22\u201325.","journal-title":"Trends Biochem Sci"},{"key":"BF6500366_CR21","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1111\/j.1463-1326.2004.00403.x","volume":"4","author":"Y Liang","year":"2005","unstructured":"Liang Y, Chen X, Osborne M, DeCarlo SO, Jetton TL, Demarest K . Topiramate ameliorates hyperglycaemia and improves glucose-stimulated insulin release in ZDF rats and db\/db mice. Diabetes Obes Metab 2005; 4: 360\u2013369.","journal-title":"Diabetes Obes Metab"},{"key":"BF6500366_CR22","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1176\/appi.ajp.160.2.255","volume":"160","author":"SL McElroy","year":"2003","unstructured":"McElroy SL, Arnold LM, Shapira NA, Keck PE, Rosenthal NR, Karim MR et al. Topiramate in the treatment of binge eating disorder associated with obesity: a randomized, placebo-controlled trial. Am J Psychiatry 2003; 160: 255\u2013261.","journal-title":"Am J Psychiatry"},{"issue":"Suppl","key":"BF6500366_CR23","doi-asserted-by":"publisher","first-page":"167S","DOI":"10.1038\/oby.2004.284","volume":"12","author":"A Astrup","year":"2004","unstructured":"Astrup A, Toubro S . Topiramate: a new potential pharmacological treatment for obesity. Obes Res 2004; 12 (Suppl): 167S\u2013173S.","journal-title":"Obes Res"},{"key":"BF6500366_CR24","doi-asserted-by":"publisher","first-page":"318","DOI":"10.2337\/diacare.15.3.318","volume":"15","author":"RA DeFronzo","year":"1992","unstructured":"DeFronzo RA, Bonadonna RC, Ferrannini E . Pathgenesis of NIDDM. A balanced overview. Diabetes Care 1992; 15: 318\u2013368.","journal-title":"Diabetes Care"},{"key":"BF6500366_CR25","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1056\/NEJM199001253220403","volume":"322","author":"GI Shulman","year":"1990","unstructured":"Shulman GI, Rothman DL, Jue T, Stein P, DeFronzo RA, Shulman RG . Quantitation of muscle glycogen synthesis in normal subjects and subjects with non-insulin-dependent diabetes by 13C nuclear magnetic resonance spectroscopy. N Engl J Med 1990; 322: 223\u2013228.","journal-title":"N Engl J Med"},{"key":"BF6500366_CR26","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1074\/jbc.274.4.1865","volume":"274","author":"MP Czech","year":"1999","unstructured":"Czech MP, Corvera S . Signaling mechanisms that regulate glucose transport. J Biol Chem 1999; 274: 1865\u20131868.","journal-title":"J Biol Chem"},{"key":"BF6500366_CR27","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1139\/h97-033","volume":"22","author":"RN Cortright","year":"1997","unstructured":"Cortright RN, Dohm GL . Mechanisms by which insulin and muscle contraction stimulate glucose transport. Can J Appl Physiol 1997; 22: 519\u2013530.","journal-title":"Can J Appl Physiol"},{"key":"BF6500366_CR28","doi-asserted-by":"publisher","first-page":"14679","DOI":"10.1074\/jbc.273.24.14679","volume":"273","author":"JT Brozinick Jr","year":"1998","unstructured":"Brozinick Jr JT, Birnbaum MJ . Insulin, but not contraction, activates Akt\/PKB in isolated rat skeletal muscle. J Biol Chem 1998; 273: 14679\u201314682.","journal-title":"J Biol Chem"},{"key":"BF6500366_CR29","first-page":"1369","volume":"47","author":"T Hayashi","year":"1998","unstructured":"Hayashi T, Hirshman MF, Kurth EJ, Winder WW, Goodyear LJ . Evidence for 5\u2032 AMP-activated protein kinase mediation of the effect of muscle contraction on glucose transport. Diabetes 1998; 47: 1369\u20131373.","journal-title":"Diabetes"},{"key":"BF6500366_CR30","doi-asserted-by":"publisher","first-page":"E677","DOI":"10.1152\/ajpendo.2001.280.5.E677","volume":"280","author":"N Musi","year":"2001","unstructured":"Musi N, Hayashi T, Fujii N, Hirshman MF, Witters LA, Goodyear LJ . AMP-activated protein kinase activity and glucose uptake in rat skeletal muscle. Am J Physiol Endocrinol Metab 2001; 280: E677\u2013E684.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"BF6500366_CR31","doi-asserted-by":"publisher","first-page":"E1015","DOI":"10.1152\/ajpendo.00169.2005","volume":"289","author":"JJ Wilkes","year":"2005","unstructured":"Wilkes JJ, Nguyen MT, Bandyopadhyay GK, Nelson E, Olefsky JM . Topiramate treatment causes skeletal muscle insulin sensitization and increased Acrp30 secretion in High-Fa \u2013 Fed Male Wistar rats. Am J Physiol Endocrinol Metab 2005; 289: E1015\u2013E1022.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"BF6500366_CR32","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1006\/bbrc.2001.4616","volume":"282","author":"J Eichhorn","year":"2001","unstructured":"Eichhorn J, Kayali AG, Austin DA, Webster NJ . Insulin activates phospholipase C-gamma1 via a PI-3 kinase dependent mechanism in 3T3-L1 adipocytes. Biochem Biophy Res Commun 2001; 282: 615\u2013620.","journal-title":"Biochem Biophy Res Commun"},{"key":"BF6500366_CR33","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/S0003-9861(02)00056-5","volume":"401","author":"MS Kim","year":"2002","unstructured":"Kim MS, Lee J, Ha J, Kim SS, Kong Y, Cho YH et al. ATP stimulates glucose transport through activation of P2 purinergic receptors in C(2)C(12) skeletal muscle cells. Arch Biochem Biophys 2002; 401: 205\u2013214.","journal-title":"Arch Biochem Biophys"},{"key":"BF6500366_CR34","doi-asserted-by":"publisher","first-page":"39653","DOI":"10.1074\/jbc.M306104200","volume":"278","author":"M Lee","year":"2003","unstructured":"Lee M, Hwang JT, Lee HJ, Jung SN, Kang I, Chi SG et al. AMP-activated protein kinase activity is critical for hypoxia-inducible factor-1 transcriptional activity and its target gene expression under hypoxic conditions in DU145 cells. J Biol Chem 2003; 278: 39653\u201339661.","journal-title":"J Biol Chem"}],"container-title":["The Pharmacogenomics Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/6500366.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/6500366","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/6500366.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T10:46:56Z","timestamp":1647946016000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/6500366"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,1,17]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2006,9,1]]}},"alternative-id":["BF6500366"],"URL":"https:\/\/doi.org\/10.1038\/sj.tpj.6500366","relation":{},"ISSN":["1470-269X","1473-1150"],"issn-type":[{"value":"1470-269X","type":"print"},{"value":"1473-1150","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,1,17]]},"assertion":[{"value":"16 August 2005","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2005","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2005","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2006","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}